Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline for smoking cessation
NCT05206370Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Placebo + Behavioral Support, 6-Week Cytisinicline + 6-Week Placebo + Behavioral Support and 12-Week Cytisinicline + Behavioral Support (3 arms). Primary endpoints: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 and Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12. Started Jan 2022; status: completed.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05206370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206370.